1051 Prediction of severe immune-related adverse events among real-world patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a SEER-medicare analysisOlajumoke A. Olateju, J. Douglas Thornton, Meghana V. Trivedi et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0
Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancerOlajumoke A. Olateju, J. Douglas Thornton, Rajender R. Aparasu et al.|Scientific Reports|2026Cited by 0